Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementThe Tumorigenic Roles of the Cellular REDOX Regulatory SystemsMolecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the ratImpairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analoguePharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound.Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte deathMicrobubble-mediated ultrasound therapy: a review of its potential in cancer treatmentA novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload.Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male miceLocalized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte deathExtraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapyLocalized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicityVitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response.Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.Nuclear interaction between ADR-induced p65 and p53 mediates cardiac injury in iNOS (-/-) mice.Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity.Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.Apoptosis in Anthracycline CardiomyopathyAnthracyclines selectively decrease alpha cardiac actin mRNA abundance in the rat heartNovel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cellsDietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications.In vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy, 5-iminodoxorubicin.Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null miceTime-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity.Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase AThe new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.Amidization of doxorubicin alleviates doxorubicin-induced contractile dysfunction and reduced survival in murine cardiomyocytesCardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric OncologGreen Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance.Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesDevelopment of a tumor-specific photoactivatable doxorubicin prodrug.Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice.
P2860
Q24628695-DF9AA2E2-10A8-4154-AA3C-0B233BA043E4Q26774894-1EA23513-DB04-4BAA-8791-10CEB9411ED8Q27729339-FE12F396-0F5D-4812-838C-39E0F4298852Q28344693-DE972246-C8DB-4452-BDBA-217BC30E0B40Q28363755-E391044C-593B-43C1-95E6-0F6976C56C3DQ28483834-C631A6DF-1798-4BB8-9125-0ECDBDDE4A22Q28579471-BD056C86-636F-4BE7-AED7-26D71B84412BQ30454718-8D5E9EA6-FD8E-4D02-9BA7-831EBC31AB06Q30461242-6659D001-DC0E-40D2-B4F1-E86FADA8CF0DQ33637455-55360163-2801-40A6-B25B-A97FD5C12BEBQ33812832-FB97FE83-C662-498B-9F86-F7233F909978Q33913340-5874AD97-600A-4BFB-B602-B311F29A27A5Q33946444-AF694508-C61A-4EAA-8224-81F0D79A2EA3Q34044370-29676D0E-DB8C-4DE7-B664-627852F43DF3Q34054263-9A063791-CA66-4AAD-BC39-BB16501FCCC6Q34102834-1DC70BBD-EE51-437A-A635-E993E27F83A8Q34207581-508AAE2F-DCCF-44EC-A77F-A054E49B7E64Q34292480-48F37E52-EB45-42A6-90ED-87906871A86BQ34361211-FB8FA4F6-6865-48F5-A084-D05779D37790Q35106932-5BDB6D04-6AD6-44C4-A75D-6E26F56E5DD9Q35158082-5D3B2C6B-8202-49E9-9540-E3095ED367B9Q35260701-937F702D-73B3-40B4-AEC3-B0724494D0D0Q35604952-1CD64B86-F8DF-4537-948D-15354AB3F2BDQ35642302-D6278AE4-D944-46FC-A710-D8CE5E7ED045Q35832113-615FE20C-527C-458B-9525-79D13D1EBEA4Q35934052-4B198121-BC61-4493-BDEB-12E00AFFED47Q35989515-703293CA-0C8D-43CE-B492-298520B6C603Q36029934-591F0126-034A-4DCD-8CDC-81FF113E30BEQ36186203-0639F7E3-1E34-4486-B8DD-36C185509F6AQ36329890-5B92D0B9-4FCB-4D9D-AEB4-6A375289D80CQ36467387-BEB1B5FB-1CBD-4DB0-86B7-CF08921176D3Q36555963-81FD4AC3-E7DA-42BD-A4AF-BBCB51F09F12Q36670985-C7C46D77-C107-4252-8978-56A336803AFAQ36732289-3A991E00-5D34-4740-A106-17A3864B602AQ36914391-DF18746E-3E80-4F35-A26C-A7DE33BF1929Q37045928-6BFE74EB-30F1-43E0-9407-FC38DA38AAABQ37061992-6306B83A-E17A-4BB6-AC62-5458EBB1D9B2Q37280632-789620A2-6020-4913-817C-F0E64E2B39B3Q37358150-997AE4C7-2515-44A2-A8CE-0C0D0CE3C896Q37359529-C8087C72-3480-4292-821C-4591791E66F4
P2860
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@en
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@nl
type
label
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@en
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@nl
prefLabel
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@en
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@nl
P1433
P1476
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
@en
P2093
P304
P407
P577
1990-10-01T00:00:00Z